Vertex says FDA expands Casgevy approval to sickle cell, beta thalassemia patients age 2+

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX

0.00
  • FDA cleared expanded use of Vertex’s CASGEVY for sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia in patients ages 2+.
  • Decision makes CASGEVY the first approved genetic therapy for both conditions in children as young as 2 years.
  • Vertex cited more than 75 activated authorized treatment centers in the U.S. to deliver the therapy through existing reimbursement pathways.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260701379449) on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.